Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Shares Sold by Harbour Investments Inc.

Harbour Investments Inc. lowered its position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 28.0% in the fourth quarter, HoldingsChannel reports. The fund owned 6,888 shares of the company’s stock after selling 2,675 shares during the quarter. Harbour Investments Inc.’s holdings in Amplify Weight Loss Drug & Treatment ETF were worth $155,000 at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Shares of Amplify Weight Loss Drug & Treatment ETF stock opened at $22.45 on Friday. The firm has a 50-day simple moving average of $22.85 and a two-hundred day simple moving average of $24.26. The company has a market cap of $4.04 million and a P/E ratio of 28.11. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $22.00 and a fifty-two week high of $28.19.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.